Chaoyuan Kuang is an Oncology physician affiliated with Albert Einstein College of Medicine. OpenAlex indexes 55 publications with 556 citations (h-index 11); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1695 Eastchester Rd Fl 2
Bronx, NY 104612375
Telephone
718-405-8404Provider last certified this registry record 31 Oct 2023.
Clinical trials
- CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
Sponsor: National Cancer Institute (NCI)
- Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy
Sponsor: Albert Einstein College of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year20255 payments
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
- STERIS CORPORATIONProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
57%Kinase inhibitor57%Stivarga51%Imatinib Mesylate49%Part D<11 patientsMetabolism & gastrointestinal
43%Serotonin-3 Receptor Antagonist24.4%Ondansetron Hcl100%Part D<11 patientsOpioid Agonist18.6%Loperamide100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2024–2024 per NIH RePORTER. The latest:
- Clinical testing of Listeria-TT and Gemcitabine in a Phase I clinical trial with PDAC patients
Loki Therapeutics, Inc
FY2024$294,962R42CA287679
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- High-throughput screening for novel drug combinations using patient-derived organoids
Biochemical Pharmacology
2026 - Phase 2 trial of CBX-12 for metastatic chemotherapy-refractory microsatellite stable colorectal cancer (ETCTN 10707).
Journal of Clinical Oncology
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Lipton, MD
Albert Einstein College of Medicine
Marina Konopleva, MD, PhD
Albert Einstein College of Medicine
Solomon Moshe, MD
Albert Einstein College of Medicine
Shlomo Shinnar, MD, PhD
Albert Einstein College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”